PYXS vs. XERS, VTYX, AKBA, VSTM, RAPT, NKTR, HOWL, AQST, ACIU, and INZY
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Xeris Biopharma (XERS), Ventyx Biosciences (VTYX), Akebia Therapeutics (AKBA), Verastem (VSTM), RAPT Therapeutics (RAPT), Nektar Therapeutics (NKTR), Werewolf Therapeutics (HOWL), Aquestive Therapeutics (AQST), AC Immune (ACIU), and Inozyme Pharma (INZY). These companies are all part of the "pharmaceutical preparations" industry.
Pyxis Oncology (NASDAQ:PYXS) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation.
Xeris Biopharma received 121 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 79.17% of users gave Pyxis Oncology an outperform vote while only 69.65% of users gave Xeris Biopharma an outperform vote.
Pyxis Oncology currently has a consensus price target of $8.80, indicating a potential upside of 102.76%. Xeris Biopharma has a consensus price target of $4.63, indicating a potential upside of 162.78%. Given Xeris Biopharma's higher possible upside, analysts plainly believe Xeris Biopharma is more favorable than Pyxis Oncology.
Pyxis Oncology has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500.
Xeris Biopharma has higher revenue and earnings than Pyxis Oncology. Xeris Biopharma is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Pyxis Oncology has a net margin of 0.00% compared to Xeris Biopharma's net margin of -37.58%. Pyxis Oncology's return on equity of -52.60% beat Xeris Biopharma's return on equity.
In the previous week, Xeris Biopharma had 15 more articles in the media than Pyxis Oncology. MarketBeat recorded 20 mentions for Xeris Biopharma and 5 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.70 beat Xeris Biopharma's score of 0.03 indicating that Pyxis Oncology is being referred to more favorably in the media.
39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 8.4% of Pyxis Oncology shares are held by company insiders. Comparatively, 4.6% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Xeris Biopharma beats Pyxis Oncology on 9 of the 16 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
